Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Withdrawn

• Conditions: Renal Cell Carcinoma
• Interventions: Other: Non-Interventional

• Registration Number: NCT02928263
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-10-07
• Study First Submitted QC: 2016-10-07
• Study First Posted: 2016-10-10
• Study Start: 2017-02-28
• Primary Completion: 2017-05-31
• Study Completion: 2017-05-31
• Status Verified: 2017-07
• Last Update Submitted: 2017-07-13
• Last Update Posted: 2017-07-17

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Diagnosis with metastatic renal cell carcinoma
• Prescription/administration of one of the IV or oral agents examined in the study

Read More

Exclusion Criteria

• Patients with other primary cancer diagnosis before RCC diagnosis
• Patients with pregnancy or HIV/AIDS

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients treated with oral agents	Non-Interventional	Metastatic renal cell carcinoma patients treated with oral agents
Patients treated with IV agents	Non-Interventional	Metastatic renal cell carcinoma patients treated with IV agents

Primary Outcome Measures

Name	Time	Method
Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC	Up to 63 months	Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.
Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC)	Up to 63 months	All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs.
Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC	Up to 63 months	Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated.
Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC	Up to 63 months	All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs.

Secondary Outcome Measures

Name	Time	Method
Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC	Up to 63 months	MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period.
Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC	Up to 63 months	MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period.

Trial Locations

Locations (1)

Bristol-Myers Squibb; 🇺🇸 Princeton, New Jersey, United States